Drug Profile
SYD 003
Alternative Names: SYD-003Latest Information Update: 12 Sep 2023
Price :
$50
*
At a glance
- Originator Synovo
- Class
- Mechanism of Action Immunomodulators; P38 mitogen-activated protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Pancreatic cancer
Most Recent Events
- 12 Sep 2023 Preclinical development of SYD 003 for Pancreatic cancer is ongoing in Germany (PO) (Synovo website, September 2023)
- 12 Sep 2023 SYD 003 is available for licensing as of 12 Sep 2023. https://synovo.com/innovation/
- 26 Jul 2016 Preclinical trials in Pancreatic cancer in Germany (PO)